Pfizer: FDA approves biosimilar to Roche's Avastin
(CercleFinance.com) - The US Food and Drug Administration approved Pfizer's biosimilar to Roche's blockbuster drug Avastin for the treatment of five types of cancer, the US biopharmaceutical firm said on Friday.
The FDA's green light concerns metastatic colorectal cancer, non-small cell lung cancer, recurrent glioblastoma, renal cell carcinoma and metastatic cervical cancer, the group said.
Pfizer's Zirabev is the drugmaker's second oncology monoclonal antibody biosimilar to be approved by the FDA, following the approval of Trazimera, the copy of another Roche anti-cancer drug, Herceptin, in March.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The FDA's green light concerns metastatic colorectal cancer, non-small cell lung cancer, recurrent glioblastoma, renal cell carcinoma and metastatic cervical cancer, the group said.
Pfizer's Zirabev is the drugmaker's second oncology monoclonal antibody biosimilar to be approved by the FDA, following the approval of Trazimera, the copy of another Roche anti-cancer drug, Herceptin, in March.
Copyright (c) 2019 CercleFinance.com. All rights reserved.